US Stock MarketDetailed Quotes

YMAB Y-mAbs Therapeutics

Watchlist
  • 11.880
  • +1.110+10.31%
Close Nov 27 16:00 ET
  • 11.880
  • 0.0000.00%
Post 20:01 ET
532.09MMarket Cap-22000P/E (TTM)

Y-mAbs Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Y-mAbs Therapeutics Q3 2024 Earnings Date

Currency：USDNov 8, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
23.26M
18.46M
-4.80M
Miss Est.
+13.73%
-9.74%
-20.64%
EPS
-0.17
-0.16
+<0.01
Beat Est.
+6.34%
+11.11%
+5.04%
Analyst Rating
Buy

Nov 18, 2024

Y-mAbs Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 6 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 24.418M--
--2024/Q4-- / 26.868M--
Nov 8, 20242024/Q318.461M / 23.263M--
Aug 12, 20242024/Q222.798M / 23.019M--
May 7, 20242024/Q119.931M / 22.220M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 24.418M--
--2024/Q4-- / 26.868M--
Nov 8, 20242024/Q318.461M / 23.263M--
Aug 12, 20242024/Q222.798M / 23.019M--
May 7, 20242024/Q119.931M / 22.220M--

Unlock Free Earnings Estimates

Y-mAbs Therapeutics Earnings Reports

  • Y-mAbs Therapeutics | 10-Q: Q3 2024 Earnings Report

    Nov 8 07:20 ET

  • Y-mAbs Therapeutics | 8-K: Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments

    Nov 8 06:59 ET

  • Y-mAbs Therapeutics | 10-Q: Q2 2024 Earnings Report

    Aug 12 07:10 ET

  • Y-mAbs Therapeutics | 8-K: Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

    Aug 12 06:56 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Nov 18, 2024

    Buy

    • Buy

      71.43%

    • Hold

      14.29%

    • Sell

      14.29%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg

    No Data

    Investment Theme Top Gainers Yesterday
    Top Gainers Yesterday
    Intraday+1.25%